Compass Pathways touts durability data for psilocybin drug in depression ahead of year-end filing

Kabir Nath, Compass Pathways CEO July 7, 2026 11:27 AM EDTUpdated 01:33 PM R&D Up­dat­ed: Com­pass Path­ways touts dura­bil­i­ty da­ta for psilo­cy­bin drug in de­pres­sion ahead of year-end fil­ing Ayisha Sharma News Reporter Com­pass Path­ways said Tues­day that pa­tients in the sec­ond of its two piv­otal psilo­cy­bin tri­als main­tained their re­sponse to treat­ment for at least six months … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER